Crosstalk between estrogen receptor and mitogen-activated protein kinase signaling in the development and progression of endometrial cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1357-1365

  Zhou, Long ^a   Cai, Bin ^a   Bao, Wei ^a   He, Yin Yan ^a   Chen, Xiao Yue ^a   Yang, Yi Xia ^a   Liu, Xue Lian ^a   Wan, Xiao Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apoptosis; Endometrial carcinoma; Estrogen receptor (ER); Mitogen activated protein kinase (MAPK); Proliferation

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ESTRADIOL; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROGESTERONE; TAMOXIFEN; UO 126;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ADENOCARCINOMA; CASE CONTROL STUDY; DISEASE COURSE; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84863289969     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182216ac9     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol. 2007;2:57-85. (Pubitemid 46448060)
3. Yang JZ, O'Flatharta C, Harvey BJ, et al. Membrane ERalpha-dependent activation of PKCalpha in endometrial cancer cells by estradiol. Steroids. 2008;73:1110-1122.
4. He YY, Cai B, Yang YX, et al. Estrogenic G proteinYcoupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 2009;100:1051-1061.
5. Molina L, Matus CE, Astroza A, et al. Stimulation of the bradykinin B(1) receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res Treat. 2009;118:499-510.
6. Fox EM, Andrade J, Shupnik MA. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids. 2009;74:622-627.
7. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537-549.
8. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-947. (Pubitemid 39626217)
9. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270:1491-1494.
10. Desouki MM, Rowan BG. SRC kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium. Clin Cancer Res. 2004;10:546-555. (Pubitemid 38173993)
11. Mizumoto Y, Kyo S, Mori N, et al. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007;98:652-658. (Pubitemid 46563440)
12. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 2003;191:229-237. (Pubitemid 36255609)
13. Oh AS, Lorant LA, Holloway JN, et al. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol. 2001;15:1344-1359. (Pubitemid 32703482)
14. Vivacqua A, Bonofiglio D, Recchia AG, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006;20:631-646. (Pubitemid 43291214)
15. Ahola TM, Manninen T, Alkio N, et al. G proteinYcoupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology. 2002;143:3376-3384. (Pubitemid 34925712)
16. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996-2009. (Pubitemid 44286700)
17. Suga S, Kato K, Ohgami T, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 2007;105:341-350. (Pubitemid 46613898)
18. Mabuchi S, Ohmichi M, Kimura A, et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology. 2004;145:1302-1313. (Pubitemid 38281014)
19. 2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 2000;60:5995-6000.
20. Duh JL, Yu R, Jiao JJ, et al Activation of signal transduction kinases by tamoxifen. Pharm Res. 1997;14:186-189. (Pubitemid 27146362)